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Abstract Lyme borreliosis (LB) is one of the most
common tick-borne diseases in the northern hemisphere. It
is a chronic inflammatory disease caused by the spirochaete
Borrelia burgdorferi. In its early stages, pathological skin
lesions, namely erythema chronicum migrans, appear. The
lesions, usually localised at the site of the bite, may become
visible from a few weeks up to 3 months after the infection.
Predominant clinical symptoms of the disease also involve
joint malfunctions and neurological or cardiac disorders.
Lyme disease, in all its stages, may be successfully treated
with antibiotics. The best results, however, are obtained in
its early stages. In order to diagnose the disease, numerous
medical or laboratory techniques have been developed.
They are applied to confirm the presence of intact
spirochaetes or spirochaete components such as DNA or
proteins in tick vectors, reservoir hosts or patients. The
methods used for the determination of LB biomarkers have
also been reviewed. These biomarkers are formed during
the lipid peroxidation process. The formation of peroxida-
tion products generated by human organisms is directly
associated with oxidative stress. Apart from aldehydes
(malondialdehyde and 4-hydroxy-2-nonenal), many other
unsaturated components such as isoprostenes and neuro-
prostane are obtained. The fast determination of these
compounds in encephalic fluid, urine or plasma, especially
in early stages of the disease, enables its treatment. Various
analytical techniques which allow the determination of the
aforementioned biomarkers have been reported. These
include spectrophotometry as well as liquid and gas
chromatography. The analytical procedure also requires
the application of a derivatization step by the use of
selected reagents.
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Abbreviations
AA arachidonic acid
ACA acrodermatitis chronica atrophicans
APCI atmospheric pressure chemical ionization
BHT butylated hydroxytoluene
BL Borrelia lymphocytoma
CNS central nervous system
DAN diaminonaphthalene
DNPH 2,4-dinitrophenylhydrazine
ECD electron capture detector
EIA enzyme immunoassay
ELFA enzyme-linked fluorescent assay
ELISA enzyme-linked immunosorbent assay
EM erythema migrans
EPA eicosapentaenoic acid
ESI electrospray ionization
FLD fluorescence detector
GC gas chromatography
GSH glutathione
GSHPO glutathione peroxidase
HNE 4-hydroxy-2-nonenal
HPCE high-performance capillary electrophoresis
HS-SPME headspace solid-phase microextraction
IFA immunofluorescent antibody assay
IFS immunoaffinity separation
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LA Lyme arthritis
LB Lyme borreliosis
LC liquid chromatography
MDA malondialdehyde
MRM multiple reaction monitoring mode
MS mass spectrometry
Neuro-Ps neuroprostanes
PCR polymerase chain reaction
PFB pentafluorobenzyl ester
PH phenylhydrazine
PUFAs polyunsaturated fatty acids
ROS reactive oxygen species
SIM single-ion monitoring mode
SPE solid-phase extraction
TBARS thiobarbituric acid reactive substances
TCPH 2,4,6-trichlorophenylhydrazine
TLC thin-layer chromatography
Introduction
In Europe and North America, Ixodes ricinus ticks are
common ectoparasites (external parasites). Many species of
viruses, bacteria and spirochaetes are found in tick vectors.
They belong to a phylum of distinctive Gram-negative
bacteria, which have long, helically coiled (spiral-shaped)
cells. Therefore, ticks are vectors of a number of diseases,
including Lyme disease, Colorado tick fever, tularaemia,
tick-borne relapsing fever, babesiosis, ehrlichiosis and tick-
borne meningoencephalitis, as well as anaplasmosis in
cattle and canine jaundice [1, 2]. The cause of Lyme
borreliosis is the activity of a single spirochaete species,
Borrelia burgdorferi. Lyme borreliosis or Lyme disease is
one of the most often identified diseases on the northern
hemisphere. In Europe and North America, approximately
85,000 and 15,000–20,000 cases are identified each year,
respectively. Noticeably, numerous cases of Lyme borreliosis
are reported in Poland, Sweden, Lithuania, Latvia, Belarus,
Austria, the Czech Republic and Slovenia [3].
When a human organism is infected with Lyme
borreliosis, the fastest occurring symptoms are inflamma-
tion and changes in the immunological system. The disease
causes noticeable damage in various organs including the
brain, central nervous system (CNS), heart, eyes, skeleton
and joints. The effects of the disease depend on the
genotype of the spirochaetes, individual immunological
system predispositions and other factors [3]. Usually,
antibiotics eliminate symptoms of the infection, especially
if the illness is treated in its early stage. If the disease is
identified long after the infection took place, delayed or
inadequate treatment can lead to more serious symptoms,
which can even become irreversible (post-Lyme borreliosis
syndromes [4]).
In this paper, methods used for diagnosing Lyme
borreliosis (LB) are reviewed. The developments in
laboratory and analytical methods used for the diagnosis
of the disease are taken into consideration and discussed in
detail. Procedures applied for the determination of LB
biomarkers are also presented. Apart from aldehydes such
as malondialdehyde (MDA) and 4-hydroxy-2-nonenal
(HNE), many other unsaturated components, e.g. isopros-
tenes and neuroprostane, are separated and determined in
biological samples. The formation of peroxidation products
generated by a human organism is directly associated with
oxidative stress. An analysis of human encephalic fluid,
blood, urine or plasma, provides much important data. The
presence of the MDA, HNE and isoprostanes was con-
firmed in various types of tissues as well as human body
fluids. The fast separation of these compounds from
encephalic fluid, urine and plasma, especially in early
stages of the disease, makes LB treatment possible. Various
analytical techniques which allow the determination of the
aforementioned biomarkers have been reported. These
include spectrophotometry as well as liquid and gas
chromatography. The analytical procedure also requires
the application of a derivatization step by the use of
selected reagents. Moreover, modern analytical techniques
including liquid chromatography coupled with tandem
mass spectrometry (LC/MS
n) or a fluorescence detector
(FLD) have been used for the determination of such
compounds.
Spectrum of Lyme borreliosis
Lyme borreliosis is a multisystemic disease caused by the
spirochaete Borrelia burgdorferi sensu lato (in Poland these
are B. burgdorferi, B. garinii, and B. afzelii), transmitted by
Ixodes ticks. Lesions are associated primarily with the
injury of the skin, joints, nervous system, and heart
infections [5–12].
Patients infected with B. burgdorferi sensu lato may
experience one or more clinical syndromes of early or late
LB. The basis for the LB diagnosis in humans is a series of
its clinical forms [13–15]. One of these is erythema migrans
(EM, creeping rash). The diagnosis is based solely on the
clinical picture. Typically, immunoserological tests towards
anti-B. burgdorferi antibodies are unnecessary. Erythema
migrans may appear at the site of a tick bite usually after 1–
3 weeks (and even after 3 months). A quickly appearing
syndrome takes the form of a macula, and quickly expands
showing central clearing. Erythema migrans disappears
within a few days of the proper antibiotic therapy, but this
fact is not tantamount to the elimination of infection.
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regression does not eliminate the infection either. Multiple
secondary EM, which shows the infection is spreading,
occurs rarely. The changes are usually smaller than those at
the primary stage and uniformly coloured.
Diagnosing Borrelia lymphocytoma (BL) requires the
determination of IgM or IgG presence in serum and its
histological confirmation. BL symptoms are noted in less
than 1% of patients, usually within a few weeks after a
tick bite, as a single, bluish red, painless nodule. BL is
most frequently localised in earlobes, nipples, and the
scrotum. BL changes may be accompanied by lymph
node enlargement.
Another kind of LB clinical form is chronic atrophic
dermatitis on limbs (acrodermatitis chronica atrophicans,
ACA). ACA diagnosis requires the determination of IgM or
IgG presence in serum and its histological confirmation. In
ACA, bluish red changes, initially with the features charac-
teristic of inflammatory edema, and later skin atrophy, are
frequently observed. They appear even many years after
infection. ACA ismostfrequentlylocalised on certain parts of
the limbs, especially legs. Less commonly, it can be the trunk.
These changes may be accompanied by leg pain which often
appears simultaneously with the main symptom of peripheral
neuropathy and changes in degenerative arthritis beneath the
affected skin. ACA is usually diagnosed in elderly people,
mostly women.
Moreover, cases of arthritis (Lyme arthritis, LA) are very
often observed. The morbidity requires laboratory confir-
mation by the determination of IgM antibodies in serum at
an early stage, or IgG antibodies at the late stage of the
disease. LA can take various clinical forms, e.g. wandering
pain in bones, joints, muscles and tendons, or chronic
arthritis (asymmetric, occurring even a few years after
infection, usually preceded by recurrent pain or arthritis).
Flu-like symptoms, including pain in joints, of varied
intensity are present in 40% of cases with erythema
migrans. They usually recede spontaneously and have no
connection with subsequent LA symptoms observed.
In B. burgdorferi spirochaete infection, myocarditis
(Lyme carditis) may also occur. A diagnosis requires the
confirmation of the presence of IgM antibodies against B.
burgdorferi in serum and cardiac dysfunction confirmed by
an ECG examination.
One of the most common effects caused by the
spirochaete B. burgdorferi is neuroborreliosis. When
diagnosing, it is necessary to identify other typical LB
symptoms, particularly erythema migrans. It is necessary to
confirm the presence of IgM or IgG antibodies against B.
burgdorferi in serum, and in the case of the brain and spinal
cord inflammation, additionally their intrathecal production.
These confirmations are needed to exclude the passive
transfer of antibodies through the blood–brain barrier. Some
patients with neuroborreliosis in the early stages of LB (the
first weeks after getting infected) show no presence of
antibodies in serum. In such cases, the test should be
repeated 2 weeks after the symptoms of the disease were
observed. The seroconversion occurring confirms the
diagnosis. In the course of neuroborreliosis, cerebrospinal
fluid (CSF) of patients with meningitis is characterized by
lymphocytic pleocytosis, a moderate increase in protein
concentration, and normal glucose concentration in serum.
In its first period, neuroborreliosis may proceed as follows:
cranial nerve palsy, nerve roots or individual peripheral
nerves paralysis, lymphocytic meninges inflammation
(meningitis), brain inflammation (encephalitis) or brain
and spinal cord (encephalomyelitis) inflammation. In the
late stage of neuroborreliosis, the following symptoms may
occur: inflammation of the brain and spinal cord (enceph-
alomyelitis), peripheral neuropathy, chronic encephalopathy
(with dominant memory and/or concentration impairment,
irritability, sleepiness and personality changes).
Laboratory diagnosis
Many achievements in the field of LB laboratory diagnosis
have been discussed and published in numerous reviews
[16–20]. In order to identify each of the Lyme disease
clinical forms (except EM), laboratory diagnosis requires a
two-stage diagnostic protocol. The first step should confirm
the presence of specific IgM or IgG (depending on the
clinical form) on the basis of the immunoenzymatic
method. In the second stage, for patients with positive or
dubious results, Western blotting methods should provide
unambiguous results. Both methods complement each other
as immunoenzymatic tests are usually characterized by high
sensitivity and relatively low specificity. Meanwhile, the
Western blot method is characterized by high specificity
with lower sensitivity. IgM antibodies can be detected as
early as in the second week of illness, but in most patients,
their presence can be observed a few weeks later. The late
stage of LB is usually characterized by the presence of IgG
antibodies.
Herpes virus infections (especially Epstein–Barr virus)
or other spirochaetes, and autoimmune diseases can cause
false positive serological test results. A seropositive result
without clinical symptoms typical of LB does not provide
the basis for diagnosing the disease and its treatment.
One of the optimal techniques for a potential diagnosis
in the early stage of LB is the polymerase chain reaction
(PCR) [16, 21]. The true frequency and clinical correlates
of PCR-documented, blood-borne infection in the spread of
Lyme disease are widely determined. PCR detection of B.
burgdorferi is a method at least three times more sensitive
than the cultivation of microorganisms for identifying
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useful for a rapid diagnosis.
PCR-based methods are useful for the laboratory
diagnosis of LB [16]. The first PCR assays for specific
detection of a chromosomally encoded B. burgdorferi sensu
lato gene were reported 20 years ago. Various other PCR
assays were subsequently developed for detection of B.
burgdorferi sensu lato DNA in clinical specimens. Given
that the number of spirochaetes in infected tissues or body
fluids of patients is very low, appropriate procedures for
sample collection and transport and preparation of DNA
from clinical samples are critical for yielding reliable and
consistent PCR results. Avariety of clinical specimens from
patients with suspected Lyme disease have been analysed
by PCR assays. Skin biopsy samples taken from patients
with EM or ACA have been the most frequently tested
specimens. Depending on the clinical manifestations of the
patients, appropriate body fluid samples can be collected
and analysed by PCR. The sensitivity of PCR assays may
be reduced by degradation of the B. burgdorferi sensu lato
DNA during sample transport, storage and processing [16].
The sensitivities of the PCR assays varied from 36 to 88%
for patients with EM and from 54 to 100% for patients with
ACA. The median sensitivities of the reported PCR assays
were in the range from 69 to 76%. The sensitivity of PCR
assays for detection of B. burgdorferi sensu lato in whole
blood (plasma or serum) and CSF specimens is low [16].
By contrast, higher PCR sensitivities were reported with
synovial fluid samples from patients with LA. Also PCR is
a very sensitive approach when it is employed to detect B.
burgdorferi sensu lato DNA in skin biopsy and synovial
fluid specimens from patients with LB, whereas the
diagnostic value of PCR assays for detection of B.
burgdorferi sensu lato DNA in blood (plasma or serum)
and CSF specimens is low. Moreover, PCR assays have not
been widely accepted for laboratory diagnosis of LB
because of low sensitivity in CSF and blood. PCR as a
diagnostic tool may be hampered by potential false-positive
results due to accidental contamination of samples with a
small quantity of target DNA. Although PCR is highly
sensitive for detection of DNA of B. burgdorferi sensu lato
in skin biopsy samples from patients with EM, such testing
is rarely necessary, as a clinical diagnosis can be easily
made if the characteristic skin lesion is present [16].
Bloodstream invasion is an important and common
mechanism for spreading the Lyme disease spirochaete.
As a result of insufficient standardization in diagnosing
infections that occur in Poland, PCR is not routinely used.
PCR can detect spirochaete DNA without specifying
whether it comes from living organisms, so a positive
result does not mean an active infection.
Generally, in a laboratory diagnosis of LB, various
methods for direct or indirect detection of B. burgdorferi
can be applied. Particular data and some examples of
methods are listed in Table 1.
The decision about diagnosis and further treatment of
patients with Lyme disease should be made only by a
physician who interprets the symptoms taking into account
the results of additional tests. A therapy at least 21 days
long is based on putting a patient on an antibiotic. The
choice of the antibiotic depends on the clinical form of the
disease and an individual’s tolerance.
Others methods of diagnosis
Laboratory diagnosis needs CSF (liquor cerebrospinalis) or
joint fluids from patients suffering from LB. The detection
of B. burgdorferi microscopically or by the cultivation of
spirochaetes derived from blood or CSF is difficult and
burdened with high rates of false results. Currently in
Poland, the study of cerebrospinal or joint fluid, in the case
of infections caused by B. burgdorferi spirochaetes, is
nonspecific and does not belong to routine diagnostic
procedures. However, it is known that in the early stages
of inflammation, the interaction between B. burgdorferi and
multinucleated granulocytes and endothelial cells is ob-
served, which leads to the generation of reactive oxygen
species, lipid peroxidation products and other inflammatory
mediators. Therefore, it is extremely important to develop
new analytical methodologies aimed at the effective
determination of lipid peroxidation products and other
mediators of inflammation, as biomarkers of LB and other
diseases.
The reaction of an organism during the infection or
persistent disease is an inflammation, which is responsible
for the damage of organs and systems. An inflammation of
various organs is linked to the production of free radicals
including reactive oxygen species (ROS). Free radicals play
an important role in numerous biological processes, some
of which are necessary for life, such as the intracellular
killing of bacteria. On the other hand, because of their high
reactivity, free radicals also can participate in unwanted side
reactions resulting in cell damage [22, 23].
When patients suffer from various diseases including
LB, free radical activity rapidly increases. This process is
also connected to lipid peroxidation, which refers to the
oxidative degradation of lipids, and is especially dangerous
for brain cells, resulting in their damage. Metabolism
processes in brain cells require more oxygen and glucose
concentrations than other cells and tissues. Moreover, brain
cells contain large amounts of polyunsaturated fatty acids
(PUFAs) and iron ions. In addition, these ions are catalysts
of certain reactions in which free radicals take part. All
these processes are induced by free radicals and their
reaction with lipids in cell membranes, which has an effect
2236 M. Ligor et al.on cell damage. This reaction involves the oxidation of
PUFAs, which are biological membrane components. The
peroxidation of cell constituents is highly correlated with
the formation of reactive aldehydes. Beside aldehydes,
many other unsaturated components are formed during lipid
peroxidation[24]. Important biomarkers of lipid peroxidation
process are MDA and HNE. Particular MDA and HNE
formation steps from PUFAs are presented in Figs. 1 and 2,
according to refs. [25, 26].
MDA and HNE are generated during all physiological
processes. However, their concentrations are sometimes
three times higher in inflammation, because free radicals
induce their synthesis [27]. These compounds display
reactive character toward nucleic acids, proteins and others
[28]. Some products of lipid peroxidation react with DNA
leading to both genotoxic and mutagenic action. In
particular, MDA is the most mutagenic, but HNE the most
genotoxic. The aforementioned compounds resulting in
DNA damage caused by adducts of lipid peroxidation
products with DNA can be removed by the repairing action
of glycosylases [28].
The increase of membrane phospholipid peroxidation
products in the course of LA has been reported [29]. ROS
generated by stimulated phagocytes located near the joints
Fig. 1 Formation of MDA during peroxidation of PUFAs [25]
Table 1 Methods recently developed for the direct and indirect determination of B. burgdorferi
Diagnosis Methods Ref.
Direct detection of B.
burgdorferi sensu lato
Microscope-based assays (have limited clinical utility in laboratory confirmation of LB because of
the sparseness of organisms in clinical samples)
[13–15]
Detection of B. burgdorferi-specific proteins or nucleic acids (detects antigens in CSF of patients
with neuroborreliosis and in urine samples from patients with suspected LB; their reliability is
poor or at best questionable)
Culture (the liquid media currently used to grow B. burgdorferi sensu lato are derived from the
original Kelly medium through various modifications made over time; cultures are incubated at
30–34 °C under microaerophilic conditions for up to 12 weeks; detection of growth is
accomplished by periodic examination of an aliquot of culture supernatant for the presence of
spirochaetes by dark-field microscopy or by fluorescence microscopy after staining with the
fluorochrome dye acridine orange or a specific fluorescence-labelled antibody)
Culture of clinical specimens (B. burgdorferi sensu lato are recovered from various tissues and
body fluids of patients with LB, including biopsy, lavage, specimens of EM skin lesions, biopsy
specimens of ACA skin lesions, biopsy specimens of borrelial lymphocytoma skin lesions, CSF
specimens, blood specimens, other tissue or fluid specimens like synovial fluid, cardiac tissue)
Molecular methods of detection—PCR analysis of clinical specimens (analysis of biopsy samples
from patients with cutaneous manifestations, blood from patients with LB, analysis of CSF
specimens from patients with neuroborreliosis, analysis of synovial fluid from patients with LA)
[16]
Molecular techniques based on PCR have been employed for confirmation of the clinical diagnosis
of suspected LB, molecular species identification and/or typing of the infecting spirochaetes in
clinical specimens or on cultured isolates, and detection of coinfection of B. burgdorferi sensu
lato and other tick-borne pathogens
Immunologic diagnosis Immunodiagnosis of antigens [3, 16]
Antibody detection methods: indirect immunofluorescent antibody assays (IFA) and a variation of
this assay using antigens attached to a membrane (FIAX), enzyme-linked immunosorbent assay
(ELISA), enzyme-linked fluorescent assay (ELFA), Western immunoblots and immunochromatographic
and dot blot assays
Newer enzyme immunoassay (EIA) antibody tests: enzyme immunoassays using recombinant antigens,
peptide-based immunoassays, combination of recombinant or peptide antigens in immunoassays
Other antibody detection methods: functional antibodies (borreliacidal antibody assays), detection of
antibodies bound to circulating immune complexes; detection of antibodies in CSF—ELISA
Cellular immune response in LB: T lymphocyte and mononuclear cell proliferation assays
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tration of peroxidation products [30]. During inflammation,
the lipid peroxidation process is additionally intensified by
the decrease in the antioxidants concentration in the lipid
phase of the biomembrane [31]. The reaction of ROS with
phospholipid PUFAs has an effect on the increased
production of superoxides and low molecular weight
aldehydes [32]. Results concerning the determination of
MDA and HNE in the plasma as well as in the urine of
patients with B. burgdorferi infection have been published
[29]. During LA the level of free form of MDA and HNE in
the plasma, as well as in the urine, is about twofold higher
in comparison with the control group [29]. The aforemen-
tioned compounds have a longer lifetime than ROS and can
diffuse through biomembranes and cause greater cell
damage. MDA and HNE are very reactive electrophilic
compounds. These compounds react with antioxidants
participating in diminishing lipid peroxidation, such as
glutathione (GSH) and glutathione peroxidase (GSHPO)
[29, 33]. High reactivity of aldehydes generated during
lipid peroxidation contributes to the fact that the estimation
of their total level in biological samples is difficult. For that
reason, other lipid peroxidation products such as prosta-
glandin F2-like compounds (including more stable isopros-
tane 8-isoPGF2α) are determined in the plasma and urine
samples obtained from patients with LA [29].
Main reactions occurring during peroxidation of PUFAs,
which result in the synthesis of isoprostanes, are presented
in Fig. 3.
Many classes of F2-isoprostanes can arise from arach-
idonic acid (AA). On the contrary, peroxidation of
eicosapentaenoic acid (EPA) is predicted to lead to the
synthesis of six classes of F3-isoprostanes, but α-linolenic
and γ-linolenic acids to two classes of E1-a n dF 1-
isoprostanes, and docosahexaenoic acid to eight classes of
D4-isoprostanes and eight classes of E4-isoprostanes. The
formation of F2-isoprostanes involves the formation of
positional peroxyl radical isomers of AA, which undergo
endocyclization to PGG2-like compounds, which are
subsequently reduced to PGF2-like compounds. F2-isopros-
tanes are formed in situ in phospholipids by free radical-
catalysed peroxidation of esterified AA and subsequently
are released in free form, presumably by phospholipases.
The scheme of the formation of various classes of
compounds from AA is presented in Fig. 4.
Methodology use for the determination of biomarkers
of Lyme borreliosis and other inflammatory diseases
Malondialdehyde
MDA exists predominantly in the enol form, and it is
highly reactive. Therefore, in laboratories MDA is obtained
by hydrolysis of 1,1,3,3-tetramethoxypropane (commercially
available compound). MDA is easily deprotonated to give the
sodium salt of the enolate.
Various methods have been developed for the determina-
tion of MDA including spectrophotometry, fluorimetric
detection, immunotests, high-performance liquid chromatog-
raphy (HPLC) and gas chromatography (GC) [25, 35, 36].
However, the preparation of biological samples before
analysis is the most critical point. In case of plasma
analysis, various types of anticoagulant can be used for
MDA assay like sodium heparin [37, 38], sodium citrate
[37] and tripotassium EDTA [37, 39, 40]. Nevertheless,
EDTA is more preferable than citrate and heparin as an
anticoagulant, because it provides the lowest limit of
Fig. 2 Pathways of PUFA peroxidation and the formation of HNE [26]
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chelation by EDTA and its weak activity e.g. as an
antioxidant [41]. Moreover, the Fe–EDTA complex can
participate in the Fenton reaction, forming OH· radicals and
overestimating the lipid peroxidation [42]. Biological
samples are stable at low temperature, which is why a
suitable storage temperature is −20 °C for a short period of
time, or even −80 °C for storage for more than 1 month [25,
37, 43]. Moreover, the antioxidant butylated hydroxyto-
luene (BHT) can be used to prevent further formation of
MDA during the assay [38, 44–46]. The preparation of
biological samples requires the application of an acid to
precipitate proteins. Various inorganic acids can be used,
e.g. sulphuric acid [39], perchloric acid [47]a n d( o r t h o )
phosphoric acid [37, 38, 40].
The determination of MDA can be performed on various
biological samples. The thiobarbituric acid reactive sub-
stances (TBARS) assay has been carried out in plasma [37,
39, 40, 44, 45, 48], serum [47], different tissues [44, 49, 50,
51] and urine [52]. Some investigations report the reaction
of TBAwith MDA and linked chromogens to lipoperoxides
in biomaterials [53]. Reaction products can be detected by
spectrophotometry (λ=532–535 nm) or colorimetry as
well as by fluorimetry (excitation at λ=532 nm and
emission at λ=553 nm) [54]. The principal reaction
between MDA and thiobarbituric acid (TBA) is presented
in Fig. 5. Formation of MDA–TBA2 adduct occurs by a
nucleophilic attack involving carbon-5 of TBA and
carbon-1 of MDA, followed by dehydration and similar
reaction with a second molecule of TBA to produce a red
pigment [55]. The intensity of the pink MDA–TBA
product formed from this condensation indicates the
extent of lipid peroxidation.
Nevertheless, the MDA assay by means of TBARS is
limited by the fact that MDA is unstable. Additionally, its
oxidation yields organic alcohols and acid [56, 57]. The use
of colorimetric or fluorimetric techniques may give some
mistakes, especially in the initial stages of human diseases
in which lipid peroxidation is lower, when compared with
the nonspecific background reaction between TBA and
Fig. 3 Proposed pathways of lipid peroxidation which lead to the synthesis of isoprostanes [24]
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trations MDA or TBARS in plasma obtained with the
methods previously developed varied over a very wide
range (0–50 mmol/L) [32, 58].
The determination of MDA by use of HPLC utilizes a
derivatization as pretreatment. TBA is also used as a
reagent for this derivatization. The separation of the
MDA–TBA2 adduct from other compounds by reversed-
phase HPLC might be difficult. Several researchers have
adapted HPLC methods so that the procedure offers some
advantages in terms of specificity, recovery and reproduc-
ibility. HPLC assay for MDA is a useful method to measure
concentrations of lipid peroxidation products in biological
samples [25, 35, 37–39]. Besides, the analytical procedure
consisting of TBA addition to the sample followed by
extraction with n-butanol has been performed. This step
avoids interference formation and extends the lifetime of
the column by removing contaminants from the incubation
Fig. 4 Formation of various classes of compounds from AA [34]
2240 M. Ligor et al.mixture [38, 59]. Moreover, the difference between detec-
tion of free and total plasma MDA is discussed [59]. Only
low amounts of free MDA are present in biological
samples, and an alkaline hydrolysis step by use of sodium
hydroxide is necessary to obtain a more complete and
uniformed release of MDA from protein–MDA complexes,
which results in a higher MDA value, when total MDA is
being considered [38, 40].
Useful detectors for the determination of MDA are UV-
Vis (λ=532 or 535 nm) [37, 38, 45, 51] and FLD [38, 46,
59, 60].
Certain methods consist of plasma sample pretreat-
ment by the acidic hydrolysis of amino acid-bound
MDA and consequent protein precipitation [47]. The
protein-free plasma is directly injected into the HPLC
system and MDA is quickly eluted (monitored at λ=
254 nm) thereby allowing rapid analyses. The LOD of
some methods is relatively low (0.012 mmol/L). Another
advantage is the low amount of plasma needed for the
analysis (50 mL).
GC is also a technique that can be used in the
determination of MDA. However, a derivatization step is
necessary prior to GC analysis. Some of the main
derivatization agents are 2,3-propanediol [61], 2-
hydrazinobenzothiazole [62] and pentafluorophenylhydra-
zine [63]. Depending on the method, either free or bound
MDA may be determined and aldehydes other than MDA
can be identified. In addition, headspace solid-phase
microextraction (HS-SPME) used for the analyses of
volatile aldehydes in biological matrices has been recently
proposed [64]. The HS-SPME has been applied to prepare
samples for MDA analysis, improving the sample prepara-
tion steps in lipid peroxidation research. A modified MDA
assay involves derivatization and HS-SPME. The product
of reaction of MDA and N-methylhydrazine is 1-
methylpyrazole, which was analysed by GC with a
nitrogen–phosphorus detector, and its detection limit was
0.0103 nmol/mL [64].
The most recent and precise methods used to assess
MDA in human plasma or serum are briefly reported in
Table 2.
4-Hydroxy-2-nonenal
Alkenals, including HNE, are strong electrophiles that react
in tissues by alkylating nucleophiles (Michael addition),
particularly sulfhydryl groups, amino groups (e.g. lysine),
and the imidazole group of histidine [73, 74]. Such
reactions can lead to structural alteration and/or cross-
linking of proteins, which in turn can cause impairment of
protein function. HNE is a relatively stable aldehyde that
can diffuse to different subcellular compartments and
interact with many different cell proteins [73]. Increased
production of HNE has been shown to indicate an increased
level of oxidative damage, which may not always be
evident using the more common marker MDA [75].
Usually, the conventional analytical method for the
quantitative determination of HNE is by derivatization with
2,4-dinitrophenylhydrazine (DNPH) that reacts with HNE
to generate 2,4-dinitrophenylhydrazones with characteristic
absorbance maxima at λ=360–390 nm. Afterwards, sepa-
ration by thin-layer chromatography (TLC) or HPLC is
possible [76–78]. This two-step method is efficient and
applicable to blood plasma samples. Moreover, the quan-
titative determination of HNE by derivatization with
3H-
labelled sodium borohydride (NaB[
3H]H4), which converts
HNE Michael adducts into
3H-labelled dihydroxy deriva-
tives, has been used as a measure of protein-bound HNE
[79, 80]. Michael adducts generated in peptides and
proteins, e.g. involving HNE–cysteine, HNE–histidine and
HNE–lysine, can be analysed by HPLC with o-phthalde-
hyde derivatization [79, 80]. Reduction of the aldehyde
group of primary HNE Michael addition products with
NaBH4, which converts them to hydroxy derivatives that
are stable to strong acid hydrolysis, forms the basis of
methods for the identification and quantification of the
HNE adducts by HPLC. By means of these techniques, it
has been established that at least 80% of the histidine
residues that are lost when low density lipoprotein (LDL) is
treated with HNE can be accounted for as the Michael
addition products, whereas the Michael addition product
accounted for 49% of the lysine residues that disappeared
upon HNE treatment. This method has also allowed one to
Fig. 5 Formation of
MDA–TBA2 adduct after
reaction between MDA and
TBA [25]
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(7–9 mol/mol LDL) and trace amounts of HNE–lysine
adducts in Cu
2+-oxidized LDL [79].
Currently, LC-ESI-MS/MS methodology is being devel-
oped. Chromatography coupled to MS is more sensitive and
selective in the quantification of HNE [73, 81]. The
determination of the sites of linkage of HNE to protein
has been carried out by use of LC/MS
n. The aforemen-
tioned method has also allowed for the characterization of
HNE-adducted apomyoglobin [82]. The procedure involves
an initial analysis by ESI-MS of the adducted protein to
determine the stoichiometry of HNE incorporation. The
adducted protein is then subjected to proteolytic digestion,
followed by direct analyses of the unfractionated digest by
ESI-MS for the localization of the sites of HNE adduction.
Proteolytic digestion using trypsin produces fragments of
suitable length for analysis by tandem MS with low-energy
collision-induced dissociation. The components containing
HNE-adducted histidine residues are identified by scanning
for precursors of m/z 266, which correspond to an
immonium ion derived from HNE adducted histidine. Last,
product ion scanning of each modified tryptic fragment is
performed to provide additional structural detail and to
confirm the results obtained by precursor ion scanning.
Table 2 Methods applied in recent years for MDA determination
Methods Derivatization Blood
anticoagulant
Sample
volume
(μL)
Concentration of MDA
(μmol/L) ± SD
Linearity
(μmol/L)
LOD
(μmol/L)
Precision Ref.
HPLC-UV/Vis
(λ=532)
TBA EDTA 250 Healthy (plasma)
0.11±0.03
0.25–1.0 0.06 Within-run <4.5% [45]
Renal patients (plasma) Between-run <10.0%
End-stage renal failure,
diabetic 0.32±0.14
End-stage renal failure,
nondiabetic 0.32±0.9
Chronic renal failure
0.14±0.06
HPLC-fluometric
(λ=515)
TBA – 50 Normotensive volunteers
plasma 0.69±0.13
0–5 0.128 –
Fluorimetry TBA EDTA 200 Healthy (plasma)
0.112±0.034
0.05–0.5 0.015 Between-run 2.0% [65]
HPLC-UV/Vis
(λ=254)
None None 50 Serum of control
0.50±0.04
0–50 0.12 – [66]
Serum of goiter 3.1±0.2
HPCE None Heparin 500 ND 10–50 12.6 3.86% [67]
HPLC-UV/Vis
(λ=310 nm)
DNPH EDTA 50 Healthy (plasma)
13.8±1.32
0–100 2.1 Within-run <4% [68]
Between-run <7%
HPLC-UV/Vis
(λ=311 nm)
DAN Heparin 100 Healthy women (plasma)
0.162±0.051
–– Between-run <9.1% [69]
Healthy men (plasma)
0.138±0.028
GC-MS PH EDTA 200 Human plasma 1.3±0.07 0. 01–15 – Within-day <2.0% [70]
Between-day <2.1%
GC-MS and
GC-ECD
TCPH –– 0.48±0.03 (ECD) 0.03–3 (ECD) 0.03 (ECD) (MS) <3.3% [71]
0.50±0.03 (MS) 0.03–20 (MS) (EDC) <3.9%
GC-MS PH EDTA 200 Healthy (plasma)
1.41±0.23
0–8 – Between-day <1.5% [72]
Unstable angina (plasma)
2.81±0.52
Stable angina (plasma)
2.40±0.60
HPLC-UV/Vis
(λ=532)
TBA EDTA 500 Control (plasma)
1.39±0.17
0.1–12 0.03 <10.0% [29]
Patients LA (plasma)
3.13±0.48
HPLC-UV/Vis
(λ=532)
TBA EDTA 500 Control (plasma)
0.85±0.25
0.15–12.2 0.03 Within-assay 8.0% [60]
Between-assay 10.0%
ND not determined
2242 M. Ligor et al.Application of this approach to the characterization of HNE-
modified apomyoglobin indicated that there were between
three and ten HNE adducts per protein molecule and that the
adduction occurred solely to histidine residues [82].
AninterestingaspectinthedetectionofHNEadductsisthe
use of antibodies. Some reports concern antibodies to HNE-
treated LDL [75, 79]. Others raised the anti-HNE-LDL
antibodies interacting with epitopes on Cu
2+-oxidized LDL
and other modified proteins [74, 83, 84]. It was observed that
the antibody–protein interactions can be partly blocked
by the HNE-modified forms of several polyamino acids,
including polylysine, polytyrosine, polyarginine and
polyhistidine [79].
With regard to the fact that HNE is very reactive with
proteins and forms stable Michael addition-type adducts, a
novel immunochemical procedure has been developed [85].
It is based on the detection of HNE trapped by a protein that
has been coated on an immunoplate. The HNE-derived
epitopes generated in the coating protein are then detected
by an ELISA using a monoclonal antibody (mAbHNEJ2)
specifictothe haptenicgroupsoftheHNE–proteinconjugates
[85]. Using this method, it was observed that a considerable
amount of HNE was released from human plasma low
density lipoproteins treated with copper ions or endothelial
cells. Furthermore, a simple and rapid ELISA method for
quantitation of HNE-modified proteins has been reported.
During this method microtiter plate wells are precoated and
blocked simultaneously with epitope-bound bovine caseins
as matrix proteins, and aldehyde-modified proteins are
quantitated by competition assay with a monoclonal anti-
body (mAbHNEJ2) specific for the HNE-histidine Michael
adduct [86].
The stability of HNE in whole venous blood stored for
different time intervals was studied [87]. The HNE content in
venous blood stored in ice was determined (Fig. 6). The
obtained results show a rapid decrease of HNE concentra-
tion, especially within the first hour after drawing the blood.
Physiological levels of HNE in human plasma are
successfully determined by use of HPLC. The measurement
of HNE in human plasma should be done within 30 min
after collection. It was established that HNE is a normal
constituent of human blood plasma, but other investigations
on its occurrence under various conditions may help to
clarify the relevance of lipid peroxidation in physiological
and pathological processes [76]. The description of some
methods applied for the determination of HNE is presented
in Table 3.
Iso- and neuroprostanes
Isoprostanes (Iso-Ps) and neuroprostanes (Neuro-Ps) are
formed by radical mechanisms and accordingly exist in
several forms which in biological matrices undergo addi-
tional transformation to other metabolites. This fact creates
a necessity to find appropriate methods to enable their
analysis. The most often mentioned techniques among
researchers involved in trying to develop new methodolo-
gies allowing the quantification and qualification of Iso-Ps
and Neuro-Ps are GC/MS and LC/MS/MS. However,
sample preparation seems to be the most critical point.
The most preferable methods are SPE. Also, TLC and
derivatization in case of GC analysis are widely used.
Choosing LC imposes the use of only the SPE with
conventional or specific immunoaffinity sorbent (immu-
noaffinity separation, IFS). Such a method simplification
and the accompanying reduction of cost and time needed
for sample preparation have created wide interest in this
method. Among useful analytical methods, ELISA [89, 90],
which may be also called enzyme immunoassay (EIA) in
the literature, should be first discussed because of its utility
as a clinical screening test.
ELISA
ELISA is a biochemical technique which is often used in
immunology to quantify an antibody or an antigen in
samples. A more specific application of this method is in
the detection of isoprostanes in clinical analysis [90–95].
Because of its low cost and easy performance, ELISA is
used widely in medicine and plant pathology [96–98].
Nevertheless, when we consider the application of ELISA
to isoprostanes we see that the estimated level of these
compounds is only semiquantitative. The main reason for
this fact may be, in compliance with Yan et al. [99], cross-
reactivity. Such an interaction may also be observed in
future investigations of other prostaglandins. Application of
GC allows one to see that ELISA overestimates the
isoprostanes level by twofold [99].
Fig. 6 Content of HNE in venous blood stored in ice vs. time of
storage [87]. Methodology: after 3 h of derivatization with DNPH the
concentration of HNE was determined by HPLC
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GC/MS should be sensitive enough to quantify all desirable
analytes after appropriate sample preparation. Because of
their properties, prostanoids need a derivatization step prior
to analysis [91, 100, 101]. SPE has to be performed twice
in order to obtain high purity of selected compounds or
greater enrichment.
Iso- and neuroprostanes from human plasma and urine
are firstly extracted with use of SPE. This step of sample
preparation may be performed using a C-18 Sep-Pak
cartridge [100, 102, 103]. Other methodologies use two
extraction steps. In the first step, reversed-phase C-18 is
applied toremove protein and lipids. Subsequently, a Sep-Pak
containingNH2 groups is used [98]. After the prostanoids are
eluted from the appropriate cartridge, they are evaporated
and then dissolved in a small amount of methanol [100,
104]. Dissolved compounds are applied to a silica TLC plate
and developed to the top in a chosen solvent system.
According to Morales et al. [100], the separation of
isoprostane (15-F2t-IsoP-M) is performed with a mixture of
ethyl acetate/acetic acid/methanol (80:0.1:20v/v/v). The
visualization of PGF2α may be done with a 10% solution
of phosphomolybdic acid in ethanol followed by heating of
the plates. Compounds, which migrated close to the acid, are
scraped and extracted from the silica with the use of ethyl
acetate/ethanol (50:50v/v). The obtained samples of 15-F2t-
IsoP-M after drying under vacuum or nitrogen are converted
to the pentafluorobenzyl ester (PFB) [101]. A second
purification with the use of TLC is performed usually in a
solvent mixture containing ethyl acetate/methanol (98:2v/v).
Visualization, similarly to the first step, is performed by
spraying with phosphomolybdic acid followed by heating.
All compounds which migrate near the PGF2α methyl
ester are then scraped and eluted with a defined volume of
ethyl acetate [100] or other solvent. The eluate is dried
(under nitrogen or vacuum) and converted to the
corresponding trimethylsilyl (TMS) ether derivative. Such
prepared samples are able to be analysed by GC/MS [101,
102, 104, 105].
A shorter and easier method for sample preparation prior
to GC/MS analysis was developed and described by Lee et
al. in 2004 [106]. Their approach is based on mixed anion
exchange solid-phase extraction (MAX-SPE), which may
be followed directly by GC/MS analysis by use of various
ionization techniques.
Various ionization techniques are frequently used in
analysis of both iso- and neuroprostanes by MS. Electron
capture negative ionization (GC/ECNI-MS) is preferable
due to its sensitivity and because it allows lower LODs
[101–103, 107–110].
In the case of very complex matrices a single-ion
monitoring (SIM) mode is often used. Additionally, multiple
reaction monitoring (MRM) enhances sensitivity and selec-
tivity of tandem instruments.
HPLC analysis of prostanoids
HPLC seems to be a more appropriate method for the
analysis of prostanoids. After sample treatment, the
obtained extracts may be directly analysed by LC without
any derivatization which was necessary in GC. However,
the purification of samples is an important step. The sample
containing prostanoids needs extraction using e.g. silica-
based SPE sorbents [29, 91, 111, 112] or immunoaffinity
sorbents [91, 111].
The plasma or other biological samples initially have to
be prepared according to an appropriate given protocol.
Biological samples with BHT and triphenylphosphine have
to be homogenized thoroughly. Then, hydrolysis of
esterified prostanoids is performed (heating after adding
of KOH solution). Afterwards, samples are diluted with
water to prevent precipitation. In the case of urine, only
alkaline solution followed by acetic acid has to be added.
Such prepared samples may be loaded on the C-18 Sep-Pak
columns [112]. Because of the low recovery obtained with
conventional C-18 columns (near 20%), it was better to use
Oasis HLB cartridges for sample extraction as, depending
on the kind of compounds, recoveries were about 80%
[111]. The eluate after SPE is evaporated to dryness under
vacuum or nitrogen and after reconstitution (usually in
mobile phase) may be analysed by HPLC.
Extraction by immunoaffinity bed
In the case of prostanoids, deuterated internal standards and
KOH have to be added to the freshly thawed plasma. After
short incubation at increased temperature the alkali is
neutralized by addition of potassium dihydrophosphate
[111]. But urine samples need only dilution in potassium
dihydrophosphate and addition of internal deuterated stand-
ards. Samples may be analysed by LC/MS after evaporating
to dryness and dissolving in mobile phase.
The literaturecontainsexamplesofapplicationsusingC-18
[29, 91, 111–114] and polar end-capped C-18 [89]c o l u m n s .
Similarly to GC where the most useful tool in prostanoids
determination was MS, in LC the same situations are
occurring. In LC/MS the most common ionization
technique is electrospray (ESI). Also atmospheric pres-
sure chemical ionization (APCI) in prostanoids analysis
is recommended [112]. The analysers applied to this aim
may be different but in almost all cases a triple quadrupole
and quadrupole ion trap (QTRAP) are preferable [89, 91,
111–113]. Beside MS, applications of other detectors are
also presented. An interesting example is the application
of electrochemical and spectrophotometric detectors [29].
Medical and analytical methods in lyme borreliosis monitoring 2245Such detection methods may be applied as an alternative
to MS only in limited cases.
The recent methods used to assess isoprostanes and
neuroprostanes are presented in Table 4.
Conclusions
Several Central European countries are characterised by the
highest incidence of tick-borne diseases in the northern
hemisphere. Molecular methods including PCR give possi-
bilities for the detection of B. burgdorferi sensu lato and
these are the most valuable detection methods. For patients
with LB involving systems other than skin, PCR sensitivity
is in general low, with the exception of patients with LA.
Beside this, PCR is not routinely used in Poland. Therefore,
an interesting alternative could be methods for the
determination of lipid peroxidation products. The lipid
peroxidation process is enhanced during LB and other
human body infections. The determination of these prod-
ucts is essential in pathologies including LB and in
toxicology associated with oxidative stress. MDA, HNE,
isoprostanes and neuroprostanes are suitable biomarkers of
various diseases, which refer to viruses and bacteria attack
on an organism and to the increased formation of free
radicals and oxidative stress as a consequence. If LB is
detected in its early stage, it may be successfully treated.
One of the possibilities is the development of methods used
for the determination of biomarkers mentioned above. These
analytical methods are characterised by high sensitivity,
precision, accuracy and are not time consuming.
The concentration of 8-isoPGF2α in plasma and urine of
LA patients could be over threefold and eightfold higher,
respectively, than that in healthy people. The ratio of free to
esterified form of 8-isoPGF2α is significantly smaller if
compared with the levels in healthy people. This indicates
that the ratio of free to esterified form of 8-isoPGF2α may be
useful as an indicator of LA. Moreover, the complementary
determination of three lipid peroxidation products (MDA,
HNE and 8-isoPGF2α) may be very helpful in the diagnosis
of LB.
From an analytical point of view, chromatography
techniques are the preferred methods to determine the true
amount of biomarkers in biological materials, once they are
reliable, specific and, moreover, without the presence of
artefacts or methodological mistakes. Comparing CG and
HPLC methodologies, both are reliable and specific, but
CG requires small sample volumes. HPLC UV-VIS is
Table 4 Methods applied in recent years for determination of iso- and neuroprostanes
Method Compound Concentration ± SD LOD
(mmol/L)
Precision/accuracy Ref.
GC/MS 8-epi-PGF2α Human plasma 1.57×10
−7 to
4.50×10
−7 mmol/L
2.71×10
−8 Within-day CV 4.3–11.1% [109]
Day to day CV 9.4–15.1%
8-iso-PGF2α Urine 1.06×10
−6±4.88×10
−7 mmol/g
creatinine
5.43×10
−8 Precision 4% [101]
Accuracy 97%
15-F2t-IsoP-M Urine (mmol/g creatinine) 2.17×10
−8 Precision 7% [100]
Normal humans 1.25×10
−5±2.44×10
−7 Accuracy 96%
Hypercholesterolaemic humans
2.31×10
−6±5.70×10
−7
Hypercholesterolaemic humans administered
antioxidants 1.22×10
−6±2.71×10
−7
F2-IsoP Urine (mmol/g creatinine) –– [115]
Healthy volunteers 2.20×10
−6±9.77×10
−7
Polytraumatized patients 1.28×10
−5±7.33×10
−6
F4-NeuroP Brain tissue from rodents 2.30×10
−8±
5.28×10
−9 mmol/g wet weight
2.64×10
−8 Accuracy 97% [116]
Brain tissue from normal humans
1.29×10
−8±1.59×10
−9 mmol/g wet weight
HPLC/MS 8-iso-PGF2α Urine (mmol/mol creatinine) –– [89]
Healthy volunteers 3.34×10
−5±7.60×10
−6
Patients with obstructive sleep apnoea
5.48×10
−5±1.98×10
−5
8-iso-PGF2α Human plasma 2.88×10
−7 mmol/L 8.14×10
−8 Intraday precision 4.68% for
plasma and 3.83% for urine
[91]
Urine 9.77×10
−7 mmol/g creatinine Interday precision 3.9% for
plasma and 2.98% for urine
2246 M. Ligor et al.widely used in clinical laboratories and there are method-
ologies utilizing small sample volume or mass with total
reliability and specificity.
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